Goodbody Health Inc. is pleased to announce today a positive adjusted EBITDA of £0.48 million in its audited Financial Statements for the year to 31 December 2021. The Company has filed the Financial Statements and Management’s Discussion and Analysis for year ending 2021 with strong results, especially in the second half of the year due to its growth in testing services. All amounts unless stated otherwise are presented in British Pounds (GBP).

Goodbody Health (AQSE: GDBY) is pleased to announce that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs. This comes as the UK authorities look to the regulation of the UK consumer cannabinoid product testing infrastructure ahead of wider compliance within the industry.

Goodbody Health (AQSE: GDBY) is pleased to announce that, following the UK Food Standard Agencies (FSA) publication of the Novel Foods approved list for CBD, the Company’s application has been authorised by the FSA to the next stage of the Novel Foods submission, being the publication of the Awaiting Evidence List. This means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress onto the final Validated list.

Goodbody Health (AQSE: GDBY) is pleased to announce that, the unaudited revenue figures for the year ended 31 December 2021 are expected to be around £17m which is 8 times 2020. Even with the expected drop off from PCR testing in 2022, the Company generated revenue, in the first two months of 2022 to the end of February, of over £3.8m showing that Q1 is still performing well.

Goodbody Health (AQSE: GDBY) is pleased to announce that, following a successful pilot project using new technology to deliver accessible, fast (available in less than 10 minutes) blood test results in the local community, it has ordered a first tranche of 100 Abbott blood testing machines (the “Abbott Machines”) for its existing UK clinic network.

Goodbody Health (AQSE: GDBY) is pleased to announce (i) its intention to initiate a normal course issuer bid (“NCIB”) through the facilities of the Canadian Securities Exchange; and (ii) the adoption of a restricted share unit plan (the “RSU Plan”).

Goodbody Health Inc. (GDBYF) is pleased to announce that it has moved up a tier from the over the counter market (“OTC”) pink market to the OTCQB market. Goodbody Health welcomes the increased compliance and scrutiny, demonstrating the strong governance of the group and allowing it to be more visible to larger investors.

Goodbody Health (AQSE: GDBY) is pleased to announce that, following its successful rollout of Goodbody testing clinics in the UK, which undertake Blood and Covid PCR testing, it has signed the lease for its first clinic premises in Vancouver, Canada.

Goodbody Health (AQSE: GDBY) is pleased to announce the rollout of its plan to introduce blood testing through its existing network of clinics while it continues to contract with more new pharmacies including 15 last week.

Goodbody Health Inc is pleased to announce its subsidiary Phytovista Laboratories has achieved another significant milestone with an extension to its ISO 17025 UKAS accreditation with a test to meet Government Chemist and the Advisory Council on the Misuse of Drugs (“ACMD”) Guidance, one of a very small number of laboratories accredited for this type of testing.

OTC Ticker change

Goodbody Health (AQSE: GDBY) announces that further to the Company’s announcement on 10 January 2022, announcing the change of the Company’s name to Goodbody Health Inc., the Company’s ISIN and SEDOL will be changed to CA3821591011 and BMH29Z0, both with effect from 8 a.m. on 1 February 2022. The Company’s existing ticker GDBY remains unchanged.